E2082 + Placebo

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy Participants

Conditions

Healthy Participants

Trial Timeline

Dec 21, 2017 → Feb 20, 2020

About E2082 + Placebo

E2082 + Placebo is a phase 1 stage product being developed by Eisai for Healthy Participants. The current trial status is terminated. This product is registered under clinical trial identifier NCT03402178. Target conditions include Healthy Participants.

What happened to similar drugs?

20 of 20 similar drugs in Healthy Participants were approved

Approved (20) Terminated (1) Active (0)

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03402178Phase 1Terminated

Competing Products

20 competing products in Healthy Participants

See all competitors
ProductCompanyStageHype Score
Use of Wearable Digital Sensors After mRNA Vaccination in AdultsModernaPreclinical
0
mRNA-0184ModernaPhase 1
0
mRNA-6231ModernaPhase 1
0
LetrozoleDr. Reddy's LaboratoriesPhase 1
26
IsotretinoinDr. Reddy's LaboratoriesPhase 1
26
FexofenadineDr. Reddy's LaboratoriesPhase 1
26
SertralineDr. Reddy's LaboratoriesPhase 1
26
Nizatidine + AxidDr. Reddy's LaboratoriesPhase 1
26
AnastrozoleDr. Reddy's LaboratoriesPhase 1
26
mRNA-1273.712ModernaApproved
0
RisperidoneDr. Reddy's LaboratoriesPhase 1
26
LamotrigineDr. Reddy's LaboratoriesPhase 1
26
Metformin + GlucophageDr. Reddy's LaboratoriesPhase 1
26
LamotrigineDr. Reddy's LaboratoriesPhase 1
26
mRNA-0184ModernaPhase 1
0
Divalproex SodiumDr. Reddy's LaboratoriesPhase 1
26
SirolimusDr. Reddy's LaboratoriesPhase 1
26
GlimepirideDr. Reddy's LaboratoriesPhase 1
26
Ziprasidone HydrochlorideDr. Reddy's LaboratoriesPhase 1
26
Naproxen sodiumDr. Reddy's LaboratoriesPhase 1
26